Preventive Cardiology & Internal Medicine & Neurology & Family Medicine
Homocysteine
Homocysteine is a sulfur-containing amino acid, an intermediate in methionine metabolism, formed by its demethylation within cells. It is not supplied by the diet – it is produced exclusively by the body – and must be rapidly metabolized by two main pathways: remethylation to methionine (dependent on vitamin B12 and folic acid via methylenetetrahydrofolate reductase – MTHFR) and transsulfuration to cystathionine and then to cysteine (dependent on vitamin B6 via cystathionine beta-synthase – CBS). Hyperhomocysteinemia – defined as a total plasma concentration >15 µmol/L in adults – results from genetic anomalies (CBS or MTHFR mutations), vitamin deficiencies (B9, B12, B6), chronic kidney disease, medications, or other acquired causes. It is recognized as an independent cardiovascular risk factor and a thrombotic factor, associated with an increased risk of myocardial infarction, stroke, venous thromboembolic disease, and, in the elderly, cognitive decline and Alzheimer's disease. However, the central paradox of homocysteine – firmly established by several randomized mega-trials since 2004 – is that the therapeutic reduction of homocysteine by B vitamins (folates + B12 + B6) is not associated with a reduction in cardiovascular events in the general population, raising the fundamental question of causality versus marker: is homocysteine more of a biomarker reflecting an unfavorable metabolic state than a direct causal agent of vascular lesions? In contrast, in specific contexts – classical homocystinuria, pregnancy, CKD, stroke prevention – managing hyperhomocysteinemia remains clinically relevant.
Biochemistry, metabolism, genetics, and reference values
- Homocysteine metabolism — enzymatic pathways and vitamin cofactors: Origin and formation: methionine (an essential amino acid derived from animal proteins) → S-adenosylmethionine (SAM) via methionine adenosyltransferase (MAT) → SAM = the primary source of methyl groups in the body → methylation reactions (DNA + RNA + proteins + phospholipids + neurotransmitters) → S-adenosylhomocysteine (SAH) → hydrolysis by SAH hydrolase → free homocysteine → SAH hydrolase works in the reverse direction if homocysteine accumulates → accumulation of SAH → inhibition of methylation reactions → pathogenic mechanism in severe hyperhomocysteinemia; remethylation pathway (primary): homocysteine → methionine → enzyme: methionine synthase (MS) → cofactor: methylcobalamin (methylated vitamin B12) → methyl donor: 5-methyltetrahydrofolate (5-MTHF) → regenerated from 5,10-methylenetetrahydrofolate by MTHFR (methyltetrahydrofolate reductase) → MTHFR cofactor: riboflavin (vitamin B2) → secondary remethylation pathway: betaine-homocysteine methyltransferase (BHMT) in the liver → betaine (trimethylglycine — supplied by beets + spinach + whole grains) → alternative methyl donor → independent of folates and vitamin B12; transsulfuration pathway (irreversible): homocysteine + serine → cystathionine → enzyme: cystathionine beta-synthase (CBS) → cofactor: pyridoxal-5-phosphate (active vitamin B6) → cystathionine → cysteine → enzyme: cystathionine gamma-lyase → cofactor: vitamin B6 → cysteine → taurine + sulfate → glutathione (major antioxidant) → transsulfuration is activated when methionine is in excess → vitamin B6 is the essential cofactor of the transsulfuration pathway → a B6 deficiency → accumulation of homocysteine due to impaired transsulfuration; regulation and factors modulating homocysteinemia: diet rich in methionine (red meat + eggs) → transient postprandial increase → this is why testing is ideally done on an empty stomach + gender: men > women (premenopausal) → estrogens stimulate remethylation → postmenopausal: homocysteine increases + age: homocysteine increases progressively with age (decline in renal function + changes in vitamin status) + smoking: increases homocysteine by 20–30% (mechanism: accelerated folate breakdown + inhibition of methylation enzymes) + alcohol: depleted hepatic folates + inhibition of MTHFR + coffee: caffeine (≥4 cups/day) slightly increases homocysteine (mechanism poorly understood) + intense physical activity: transient increase followed by long-term decrease; reference values and classification of hyperhomocysteinemia: total fasting plasma homocysteine (tHcy): normal in adults: 5–15 µmol/L → optimal range according to some experts: <10 µmoll (refsum 2004 — journal of internal medicine) → légèrement modérée : 15–30 30–100sévère (homocystinurie)>100 µmol/L → pre-analytical: sample collected in EDTA or heparin lithium → rapid centrifugation (within 1 hour) → frozen plasma if delayed assay → homocysteine continues to be released by red blood cells in vitro if the sample is not centrifuged → false positives due to delayed processing + assay methods: HPLC (high-performance liquid chromatography) — reference method + immunoassay (FPIA + CLIA) — routine method in clinical laboratories + analytical sensitivity: 0.5–1 µmol/L
- Causes of hyperhomocysteinemia — genetic and acquired: Genetic causes: classic homocystinuria due to CBS (cystathionine beta-synthase) deficiency: autosomal recessive inheritance → mutations in the CBS gene (chromosome 21q22.3) → >160 mutations described → incidence: 1 in 200,000–1 in 300,000 births → clinical presentation: homocysteine >100–400 µmol/L + very high methioninemia + massive homocystinuria in the urine → manifestations: lens dislocation (ectopia lentis) + Marfanoid features + early-onset osteoporosis + arterial and venous thromboembolism (early-onset stroke and myocardial infarction, starting in childhood) + variable mental retardation → two subtypes: pyridoxine responder (50–70% of cases): high-dose vitamin B6 → normalization of homocysteine → non-pyridoxine responder: treatment with a methionine-restricted diet + supplementation with cysteine + betaine + vitamin B6 + folates → C677T mutation in the MTHFR gene (thermolabile): a very common variant in the general population (TT homozygosity: 10–15% of the Caucasian population + up to 25% in certain Mediterranean populations) → 30–60% reduction in MTHFR enzyme activity in TT individuals → moderate increase in homocysteine (2–4 µmol/L on average) → only if accompanied by folate deficiency → riboflavin (B2) cofactor: supplement TT homozygotes with folate → Frosst 1995 — Nature Genetics: identification of the C677T variant → MTHFR A1298C mutation: less studied → modest impact on homocysteine + combined C677T/A1298C variant: more pronounced effect → methionine synthase (MTR) and methionine synthase reductase (MTRR) mutations: rare deficiency → moderately elevated homocysteine + hypomethioninemia → methylmalonic acidemia if cobalamin is affected → acquired and drug-induced causes: vitamin deficiencies (most common): folate (B9) deficiency: the main cause of moderate hyperhomocysteinemia in the general population → diet low in green vegetables + malabsorption (celiac disease + intestinal resection) + alcoholism + pregnancy (increased needs) + folate-antagonist medications → vitamin B12 (cobalamin) deficiency: vegans + strict vegetarians + atrophic gastritis (anti-intrinsic factor antibodies — Biermer’s anemia) + gastric resection + terminal ileal disease (Crohn’s) + age (>65 years) + metformin (reduced ileal absorption of B12 — De Jager 2010 — BMJ: metformin × B12 deficiency → increased homocysteine) → vitamin B6 deficiency: less common as an isolated cause → alcoholism + malabsorption; chronic kidney disease (CKD): major cause of acquired hyperhomocysteinemia → eGFR <60 mL/min → elevated homocysteine in 85–100% of hemodialysis patients → mechanism: reduced renal transsulfuration + remethylation deficiency + accumulation of SAH → Moustapha 1998 — Kidney International: CRF → homocysteine inversely correlates with GFR → drugs causing hyperhomocysteinemia: methotrexate (DHFR inhibitor + folate depletion) + phenytoin + carbamazepine (enzyme inducers + accelerate folate catabolism) + valproate (methionine synthase inhibitor) + cholestyramine (folate chelator) + metformin (B12 deficiency) + prolonged high-dose PPIs (B12 malabsorption) + isoniazid (vitamin B6 antagonist) + trimethoprim + pyrimethamine (DHFR inhibitors) + cyclosporine + tacrolimus (mechanism poorly understood) + N2O (nitrous oxide — irreversibly oxidizes methylcobalamin → inactivation of methionine synthase → acute hyperhomocysteinemia + neuropathy); hypothyroidism: general slowing of metabolism + reduced synthesis of remethylation enzymes → treatment with L-thyroxine → partial normalization + smoking + obesity + menopause + sedentary lifestyle + high-calorie diet rich in methionine (red meat)
Clinical associations, diagnosis, and management
| Clinical aspect / association | Mechanisms, Data, and Modalities | Key studies and recommendations |
|---|---|---|
| Homocysteine and Cardiovascular Risk — Association, Causality, and the B Vitamin Paradox AVC — IDM — MACE — meta-analyses — RCT trials vitamin B — Mendelian randomization |
Mechanisms by which homocysteine may damage blood vessels: vascular oxidative stress: oxidation of homocysteine → free radicals (reactive oxygen species — ROS) → lipid peroxidation + LDL oxidation → endothelial dysfunction → Outinen 1998 — Biochemical Journal: homocysteine → increased ROS production in human endothelial cells + inhibition of nitric oxide (NO): homocysteine inhibits eNOS → reduced NO bioavailability → vasoconstriction + platelet aggregation + leukocyte adhesion + activation of coagulation: homocysteine → activation of factor V + factor X + inhibition of protein C + inhibition of thrombomodulin + platelet activation → prothrombotic state + altered DNA and histone methylation: accumulation of SAH → hypomethylation → genomic instability + aberrant expression of pro-atheromatous genes + thickening of the arterial media and intima: stimulation of smooth muscle cell proliferation; epidemiological association — observational meta-analyses: Boushey 1995 — JAMA: pioneering meta-analysis of 27 studies → 5 µmol/L increase in homocysteine → risk of coronary heart disease +20% (OR 1.2) + risk of stroke +40% (OR 1.4) + risk of VTE +60% → documented dose-response association → Homocysteine Studies Collaboration 2002 — JAMA: meta-analysis of 30 prospective studies (n=5,073 coronary cases + 1,113 cerebrovascular cases) → 3 µmol/L reduction in homocysteine → estimated 16% reduction in coronary risk % + 24% reduction in stroke risk % → suggested a causal relationship; paradox of randomized B-vitamin trials — negative results: HOPE-2 (Lonn 2006 — NEJM): n=5,522 patients at high cardiovascular risk → folic acid 2.5 mg + B6 50 mg + B12 1,000 µg/day × 5 years vs. placebo → homocysteine reduction of 3.3 µmol/L → no reduction in major adverse cardiovascular events (MACE) → no reduction in MI → slight reduction in strokes (not significant) → NORVIT (Bønaa 2006 — NEJM): n=3,749 post-MI → folic acid + B6 + B12 → reduction in homocysteine → no reduction in cardiovascular risk → signal of increased risk in certain subgroups → VITATOPS (Hankey 2010 — Lancet Neurology): n=8,164 patients with recent stroke or TIA → B vitamins → reduction in homocysteine → no reduction in MACE → SEARCH (Armitage 2010 — JAMA): n=12,064 survivors of myocardial infarction → folic acid + B12 → no cardiovascular benefit → partial exception: Huo 2015 meta-analysis — JAMA: analysis of 15 RCTs, n=71,422 patients → folate + B12 ± B6 → significant 10% reduction in stroke risk (RR 0.90 — 95% CI % 0.84–0.97) → benefit limited to strokes (not MI) → more pronounced in patients without folate fortification (countries without mandatory food fortification) → Wang 2015 meta-analysis — JAMA Internal Medicine: confirmed stroke → 10% reduction → greater in countries without dietary folate fortification; Mendelian randomization — causality questioned: Casas 2005 — Lancet: Mendelian randomization using MTHFR C677T variants → TT subjects have chronically elevated homocysteine levels of 2–3 µmol/L → if homocysteine were causal → TT subjects should have a higher cardiovascular risk → meta-analysis: OR for stroke = 1.26 for TT → slight association → but: the observed effect on stroke is small + Wald 2002 — BMJ: meta-analysis of Mendelian randomization → association between C677T homozygotes and moderately increased cardiovascular risk → but RCTs of B vitamins (which reduce homocysteine by more than the 2–3 µmol/L difference attributed to genetic variations) show no reduction → current general conclusion: homocysteine is a biomarker associated with cardiovascular and thrombotic risk + likely an indicator of adverse metabolic states (vitamin deficiencies + chronic kidney disease + inflammation) rather than a direct causal factor in atherosclerosis | Position of Learned Societies on the Screening and Treatment of Hyperhomocysteinemia for Cardiovascular Purposes: SCC (Canadian Cardiovascular Society) + ESC (European Society of Cardiology) + AHA/ACC: Systematic measurement of homocysteine as a cardiovascular risk stratification tool is not routinely recommended in the general population → Reduction of homocysteine by B vitamins is not recommended as primary or secondary cardiovascular preventive treatment (Level of Evidence A) → Exceptions: Screening is recommended in situations with a high risk of severe hyperhomocysteinemia: suspected homocystinuria + thrombosis at a young age (<45 years) without other factors + family history of early cardiovascular event + known or suspected vitamin B12 deficiency + CKD + pregnancy (prenatal assessment) → Folic acid + B12 supplementation remains indicated for: prevention of neural tube defects (pregnancy) + correction of documented deficiencies + management of classic homocystinuria + prevention of stroke in countries without food fortification with folic acid (Huo 2015 JAMA); USPSTF 2017: no recommendation on screening for hyperhomocysteinemia in the general population + Refsum 2004 — Journal of Internal Medicine: consensus review → optimal homocysteine 10 µmol/L with risk factor |
| Homocysteine and Neurological Risk — Stroke, Cognitive Decline, and Alzheimer's Disease Ischemic stroke — dementia — Alzheimer's — brain atrophy — folate — B12 — cognitive trials |
Association between homocysteine and ischemic stroke: mechanisms specific to cerebral circulation: homocysteine increases susceptibility to cerebral ischemia through: neuronal excitotoxicity → homocysteine is a partial agonist of NMDA receptors → excessive activation → intracellular calcium influx → neuronal death (Lipton 1997 — Nature Medicine) → cerebral endothelial dysfunction + small vessel thrombosis (leukoaraiosis) + increased carotid arterial stiffness → thickening of the IMT (Intima-Media Thickness) + accelerated atherogenesis → epidemiological association with stroke: Rotterdam Study (Vermeer 2002 — Annals of Neurology): homocysteine >18 µmol/L → 2.5-fold increased risk of stroke vs. normal homocysteine → subcortical atherosclerosis + leukoaraiosis → dose-response relationship → effects of B vitamins on stroke: Huo 2015 — JAMA: meta-analysis → 10% reduction in stroke risk (RR 0.90) → more pronounced in countries without folate fortification → benefit primarily in primary stroke prevention + VISP (Toole 2004 — JAMA): n=3,680 stroke patients → high-dose B vitamins vs. standard doses → no significant reduction in vascular events → but significant reduction in the subgroup without contraindications to B12; Association between homocysteine and dementia: neuropathological mechanisms: hypomethylation of neuronal DNA and histones → dysregulation of gene expression + accumulation of SAH → inhibition of methylation reactions in the brain (synthesis of membrane phospholipids and neurotransmitters — serotonin, dopamine, norepinephrine) + neuronal oxidative stress + NMDA neurotoxicity (partial agonist) + impaired myelin synthesis (B12 deficiency → SAM deficiency → hypomethylation of basic myelin) → Seshadri 2002 — NEJM: Framingham Heart Study → prospective cohort → homocysteine >14 µmol/L → doubled risk of Alzheimer’s disease (RR 1.8 — 95% CI 1.3–2.5) + 1.4-fold increased risk of any dementia → seminal study → B vitamins in Cognitive Decline (Smith 2010 — PLOS ONE): n=168 patients with mild cognitive impairment (MCI) → B vitamins (folic acid 0.8 mg + B6 20 mg + B12 0.5 mg) × 2 years → 30% reduction in brain atrophy vs. placebo (volumetric MRI) → reduction correlates with lower homocysteine levels → de Jager 2012 — PLOS ONE: subgroup of the previous trial → vitamin B → accelerated reduction in cognitive decline in temporal and hippocampal regions → more pronounced effect if Ω-3 levels are high concurrently (Jernerén 2015 — American Journal of Clinical Nutrition: beneficial interaction of B vitamins + Ω-3 on gray matter → VITACOG trial) → COSMOS-Mind (Baker 2022 — American Journal of Clinical Nutrition): n=2,262 → no benefit of B vitamins on overall cognition → but positive signal in subgroups with elevated homocysteine at baseline | Clinical and practical implications in neurology and family medicine: neurological evaluation of dementia or cognitive decline: measurement of plasma homocysteine → serum B12 + erythrocyte folate → if B12 is low or borderline (<250 pmol/L) → supplement → if homocysteine >15 µmol/L with cognitive impairment → supplement with folate + B12 ± B6 → even if benefit not proven in RCTs for established dementia → treating documented deficiencies is unequivocally recommended → NICE Guidelines UK 2018 + Canadian Consensus Conference on Diagnosis and Treatment of Dementia 2020: B12 + folate testing recommended in the evaluation of all cases of dementia → treat deficiencies; vitamin B12 deficiency and homocysteine in the elderly: prevalence of B12 deficiency >65 years: 10–20% → atrophic gastritis + intrinsic factor deficiency → malabsorption of dietary B12 (not supplemental B12 or crystalline synthetic B12) → metformin → documented B12 deficiency (Reinstatler 2012 — Diabetes Care) → screen for B12 in all patients on metformin for ≥4 years or at high doses → supplement if B12 <300 pmol/L (safety margin) → serum methylmalonic acid (MMA): functional marker of B12 deficiency (more sensitive than serum B12 alone) → elevated MMA + low B12 + elevated homocysteine → functional B12 deficiency → normal MMA + normal B12 = no deficiency |
| Homocysteine and thrombosis, pregnancy, and specific populations MTEV — thrombophilia — pregnancy — neural tube defects — MTHFR — CKD — homocystinuria |
Homocysteine and venous thromboembolism (VTE): prothrombotic mechanisms: homocysteine → activation of Factor V Leiden → inhibition of thrombomodulin → activation of Factor X + Factor Va → resistance to activated protein C → venous thrombosis + platelet activation by thromboxane A2 → epidemiological association with VTE: den Heijer 1996 — Annals of Internal Medicine: case-control study → hyperhomocysteinemia (>18.5 µmol/L) → 2.5-fold increased risk of recurrent VTE → Ridker 1997 — Journal of the American Medical Association: Physicians Health Study cohort → elevated homocysteine → VTE RR 3.4 in the top quintile → den Heijer 2005 — Thrombosis and Haemostasis: meta-analysis → mild hyperhomocysteinemia → OR for VTE = 2.1 → modest association + role in thrombophilia screening: standard thrombophilia screening includes homocysteine measurement in certain contexts: VTE at a young age (<45 years) without other triggering factors + recurrent VTE + VTE in unusual locations (vena cava, mesenteric, or cerebral thrombosis) + premarital or prenatal evaluation with a family history of VTE → current position: MTHFR C677T testing (genotyping) is not recommended as a routine part of thrombophilia screening → ACCP (American College of Chest Physicians) + ASH (American Society of Hematology) 2020: the MTHFR genotype alone is a very low risk factor for VTE → homocysteine testing is preferable to MTHFR genotyping + correction of vitamin deficiencies prior to any long-term anticoagulant therapy if hyperhomocysteinemia is present; pregnancy and homocysteine — neural tube defects and obstetric complications: role of folates and homocysteine in embryogenesis: folate → synthesis of purines and pyrimidines → cell division → neural tube closure (days 21–28 of embryogenesis) → folate deficiency → hyperhomocysteinemia → neural tube defects (anencephaly + spina bifida) → Czeizel 1992 — NEJM: randomized trial → folic acid supplementation (0.8 mg/day) during the periconceptional period → 70% reduction in the incidence of neural tube defects → MRC Vitamin Study 1991 — Lancet: folic acid (4 mg/day) in women with a history of neural tube defects → 72% reduction in recurrence → recommendations: folic acid 0.4–0.8 mg/day for at least 3 months before conception through 12–16 weeks of gestation → 5 mg/day if history of neural tube defects or epilepsy on anticonvulsants + other obstetric complications associated with hyperhomocysteinemia: preeclampsia + recurrent miscarriages + intrauterine growth restriction (IUGR) + placental abruption → Vollset 2000 — American Journal of Obstetrics and Gynecology: meta-analysis → hyperhomocysteinemia → RR for preeclampsia 3.2 + IUGR 2.4 + recurrent miscarriages 2.7 → supplement with folate + B12 + B6 in pregnant women with hyperhomocysteinemia + homocysteine and pregnancy in women with MTHFR C677T TT: folate deficiency + TT homozygosity → increased risk of neural tube defects → routinely supplement + homocysteine and CRF: Moustapha 1998 — Kidney International: homocysteine >15 µmol/L in 85–100% of dialysis patients → mechanism: reduced renal transsulfuration + enzyme deficiency → homocysteine is an additional cardiovascular risk factor in CKD (already at very high risk) → treatment of hyperhomocysteinemia in CKD: folates 5–15 mg/day + B12 + B6 → 25–30% reduction in homocysteine → but: HOST trial (Jamison 2007 — JAMA): n=2,056 patients with advanced CKD → high doses of B vitamins → reduction in homocysteine → no reduction in mortality or cardiovascular events → results similar to cardiovascular trials: homocysteine reduction without clinical benefit → nevertheless: correcting documented vitamin deficiencies remains recommended + homocysteine reduction in CKD may improve endothelial markers (Mallamaci 2002 — Journal of Nephrology) | Treatment and management of hyperhomocysteinemia based on the clinical context: treatment of underlying vitamin deficiencies (top priority): documented folate deficiency: folic acid 1–5 mg/day PO × 3–4 months → then maintenance dose of 0.4–1 mg/day depending on the cause → documented B12 deficiency: cyanocobalamin or hydroxycobalamin IM 1,000 µg/day × 7 days → then 1,000 µg/week × 4 weeks → then 1,000 µg/month (maintenance) → or high-dose oral B12: 1,000–2,000 µg/day PO if intestinal absorption is preserved (passive absorption — intrinsic factor-independent) → sublingual B12: equivalent to the IM route in some studies (Kuzminski 1998 — Blood) → B6 deficiency: pyridoxine 50–100 mg/day; empirical supplementation without documented deficiency — limited indications: homocystinuria due to CBS deficiency responsive to B6: pyridoxine 200–1,000 mg/day → partial or complete response in 50–60% of cases → reduction of homocysteine toward normal levels → betaine (trimethylglycine): 3–6 g/day → alternative methyl donor (BHMT pathway) → indicated if non-responsive to B6 in homocystinuria + CRF with documented hyperhomocysteinemia + pregnant women with hyperhomocysteinemia: folates + B12 → correction before and during pregnancy → summary table of vitamin supplementation: folates 0.4–0.8 mg/day: neural tube defect prevention (all women of childbearing age) → folates 5 mg/day: history of neural tube defect + epilepsy + multiple pregnancy → B12 1,000 µg/month IM or 1,000–2,000 µg/day PO: documented deficiency → B6 50–100 mg/day: documented deficiency + CBS-responsive homocystinuria; foods rich in natural folate (5-MTHF): green vegetables (spinach + broccoli + asparagus + romaine lettuce) + legumes (lentils + chickpeas + beans) + liver + orange juice → folic acid fortification of foods in Canada: since 1998 — PHAC: wheat flour + cereal products → mandatory folic acid fortification → 150 µg/100 g of flour + 46% reduction in the incidence of neural tube defects in Canada since 1998 (De Wals 2007 — NEJM: Canadian study) → foods rich in B12: meat + fish + seafood + eggs + dairy products → vegans: systematic supplementation recommended |
| Biological diagnostic - prescription and interpretation of dosage Indications - pre-analytical - results - complementary assessment - MTHFR genotyping - AMM - B12 - folate |
Indications for plasma homocysteine testing: indications recognized by guidelines: etiological evaluation of deep vein thrombosis or pulmonary embolism in young patients (<45 years) without an obvious precipitating factor + comprehensive thrombophilia workup + stroke or TIA in young adults (<50 years) + family history of early-onset cardiovascular disease + documented B12 or folate deficiency → assessment of residual thrombotic risk + therapeutic monitoring of classic homocystinuria + prenatal evaluation if family history of neural tube defects + evaluation of dementia or cognitive decline + moderate to severe chronic kidney disease (eGFR <45 mL/min) → cardiovascular assessment + nutritional assessment + patients on methotrexate (long-term) + HIV patients on certain ARVs + questionable indications (insufficient data for universal recommendation): cardiovascular screening for primary prevention in the general adult population → not recommended (USPSTF 2017) + systematic assessment of overall cardiovascular risk → the Framingham score remains the most validated + post-MI or post-stroke assessment outside the contexts listed above; pre-analytical and interpretation: sample collection conditions: EDTA or lithium heparin plasma → centrifugation within one hour → plasma frozen at –20°C if testing is delayed → ideally on an empty stomach (12 hours) because meals high in methionine transiently increase homocysteine by 20–30% → homocysteine continues to be released by red blood cells if the tube is not centrifuged → significant false positives if there is a delay before centrifugation + systematic additional testing in cases of confirmed hyperhomocysteinemia: serum vitamin B12 + erythrocyte (or serum) folates + vitamin B6 (plasma pyridoxal-5-phosphate) + serum methylmalonic acid (MMA) if functional B12 deficiency is suspected → CBC (macrocytosis → B12 + folate deficiency) + creatinine + eGFR (CRF) + TSH (hypothyroidism) + liver function tests (liver disease) + methioninemia if severe homocystinuria is suspected + urinary homocystinuria (urinary amino acid chromatography) if classic homocystinuria + MTHFR C677T and A1298C genotyping: limited indications → ASH + ACCP 2020: not recommended as a routine part of thrombophilia workup → low clinical utility because the result does not alter management (treatment = correction of vitamin deficiencies regardless of genotype) → may be requested in specific contexts: research + family planning + enzyme-related homocystinuria → but not for routine screening | Practical decision algorithm in Quebec — elevated homocysteine: Step 1 — confirm hyperhomocysteinemia (fasting, rapid centrifugation) + Step 2 — complete etiological workup: B12 + red blood cell folate + B6 + MMA + CBC + creatinine + eGFR + TSH → Step 3 — identify and treat the cause: B12 deficiency → supplement (IM or high-dose oral) → folate deficiency → folic acid 1–5 mg/day → B6 deficiency → pyridoxine 50 mg/day → CKD → optimize dialysis + high-dose folate → medication causing hyperhomocysteinemia → adjust or substitute → hypothyroidism → treat thyroid → Step 4 — re-evaluate homocysteine after 8–12 weeks of treatment: normalization expected if the cause is corrected → persistence despite correction of deficiencies → consider a genetic cause (CBS + MTHFR thermolabile + others) → medical genetics consultation → Step 5 — contextualize risk: isolated elevated homocysteine without deficiency and without other risk factors → does not warrant additional vitamin treatment in non-pregnant adults (negative RCT data) → treat comorbidities (CKD + hypothyroidism + medications) + correct deficiencies + optimize modifiable cardiovascular risk factors (HTN + diabetes + smoking + dyslipidemia); In Quebec — RAMQ reimbursement: plasma homocysteine assay: reimbursed with medical indication (prescription) → thrombophilia workup + dementia workup + CKD + homocystinuria + high-risk pregnancy monitoring + MTHFR genotyping: not routinely reimbursed → private laboratories only → advise with caution (limited clinical impact) + folic acid 5 mg/tablet: reimbursed on RAMQ list → folic acid 1 mg: over-the-counter + oral B12 1,000 µg: over-the-counter (pharmacy) → IM B12 (cyanocobalamin): prescription required |
ℹ️
Reducing homocysteine with B vitamins does not reduce cardiovascular risk — but correcting deficiencies remains essential: Mega-randomized trials (HOPE-2, NORVIT, SEARCH, VITATOPS) have shown that folate and B vitamin supplementation, while effective in reducing plasma homocysteine, does not decrease major cardiovascular events in the general population. Homocysteine is likely more of a biomarker than a causal factor. In contrast, correcting a documented deficiency in B12, folate, or B6 remains a clinical priority—in pregnant women, patients on metformin, the elderly, vegans, or those with kidney failure.
Situations Requiring Urgent Medical Attention
Stroke or Transient Ischemic Attack in a young adult (<50 years old) with no obvious classical cardiovascular risk factors → homocysteine level in thrombophilia workup + B12 and folate deficiency workup → consider classic homocystinuria (CBS) if homocysteine >50–100 µmol/L → reference in metabolic genetics.
Deep vein thrombosis or pulmonary embolism in a young patient (<45 years old) without an obvious trigger, or thrombosis in an unusual location (mesenteric vein + cerebral vein + vena cava) → comprehensive thrombophilia workup including homocysteine → treat vitamin deficiencies if found before long-term anticoagulation.
Acute confusion or rapid neurological deterioration in a patient using recreational nitrous oxide (N₂O) frequently or under repeated anesthetic use, or in an unsoupplemented vegan patient irreversible oxidation of methylcobalamin by N₂O → inactivation of methionine synthase → acute hyperhomocysteinemia + neuropathy → measure B12 + homocysteine + MMA → urgent IV supplementation with hydroxycobalamin (resistant to oxidation by N₂O — unlike cyanocobalamin).
Newborn with lens dislocation + Marfanoid morphology + psychomotor delay + neonatal thromboembolism Classical homocystinuria due to CBS deficiency → pediatric metabolic emergency → homocysteine + methionine + urinary homocystine assay → immediate consultation with pediatric genetics and metabolism.
Consult at Clinique Omicron
Clinique Omicron physicians prescribe homocysteine testing in appropriate clinical settings, complete vitamin assessments (B12, folate, B6), initiate supplementation if a deficiency is documented, and monitor at-risk patients (pregnancy, CKD, patients on metformin, cognitive decline). Consultations are available at several service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute medical advice. An elevated homocysteine result should always be interpreted in its full clinical context by a qualified healthcare professional.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.